India, Nov. 24 -- The board of ERIS Lifesciences at its meeting held on 24 November 2025 has approved the acquisition of balance 30% of the total share capital of Swiss Parenterals, a subsidiary of the Company.Further, the board has approved the issuance of up to 23,06,372 equity shares of the Company on preferential basis to discharge the consideration for acquisition of 30% stake in Swiss Parenterals.
Published by HT Digital Content Services with permission from Pivotal Sources....